Competitor Analysis: Dengue Virus Vaccines and Therapeutics

La Merie Publishing, July 2012, Pages: 27

The present Competitive Intelligence Report about Dengue Virus Vaccines & Therapeutics provides a competitor evaluation in the field of investigational vaccines and therapeutics against one or more serotypes of Dengue Virus for prophylaxis or treatment of Dengue fever as of July 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

It is estimated that about 100 million cases of infection by Dengue virus occur each year and that nearly half the world’s population is at risk of Dengue virus infection. At present, no vaccines are available to prevent infection with mosquito-borne Dengue virus. There are four serotypes of Dengue virus, and neutralizing antibodies are serotype-specific with the risk of sequential infections. Although immunity against a specific serotype is life-long, but previous infection with one serotype is a risk factor for a more severe form of Dengue (Dengue hemorrhagic fever) upon subsequent infection with another serotype, thus emphasizing the need for a tetravalent vaccine against all four serotpyes of Dengue virus.

The report includes a compilation of currently active projects in research and development of vaccines targeting Dengue virus for prophylaxis of Dengue fever and of therapeutics for treatment of Dengue fever. In addition, the report lists company-specific R&D pipelines of Dengue Virus Vaccines & Therapeutics.

Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Competitor Analysis: Dengue Virus Vaccines and Therapeutics

Index
- Dengue Virus Vaccines
- Dengue Virus Vaccines from NIH / NIAID
- Dengue Virus Vaccines Licensed from NIH to Manufacturers in Developing Countries
- Dengue Virus Therapeutics
- CorporateDengue Virus Vaccines & Therapeutics R&D Pipeline
- About La Merie

- AltraVax
- Biological E
- GenPhar
- GenVec
- GlaxoSmithKline
- Inovio
- Instituto Butantan
- Invirogen
- Janssen Pharmaceutica
- Medivir
- Merck
- Nanoviricides
- National Institute of Allergy & Infectious Diseases (NIAID)
- Naval Medical Research Center (NMRC)
- Novartis Institute for Tropical Diseases (NITD)
- Oswaldo Cruz Foundation (Fiocruz)
- Panacea Biotec
- Sanofi Pasteur
- Siga Technologies
- Themis Biosciences
- Vabiotech
- Vical
- Walter Reed Army Institute of Research (WRAIR)

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Stakeholder Opinions: Tropical Diseases - Dengue, Japanese encephalitis and West Nile virus - Increasing attention for neglected diseases
• Tropical Diseases: Treatment, Prevention, and Market Opportunities
• Emerging Microbiology Tests and Companies Developing New Technologies and Products
• Competitor Analysis: Malaria Vaccines & Therapeutics
• Mucocutaneous Manifestations of Viral Diseases. An Illustrated Guide to Diagnosis and Management. Edition No. 2
• Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates
• Molecular Diagnostics - Technologies, Markets and Companies
• Analysis of Emerging Microbiology Tests and Strategic Profiles of Leading Suppliers
• Advances in Vaccine Technology and Delivery
• New Generation Vaccines. Edition No. 4